System Issue At CVS Caremark Leaves Patients Stranded Without Medications

Starting Monday morning, patients covered by CVS's Caremark business experienced a halt in prescription processing, leaving some without their medications.

Starting Monday morning, patients covered by CVS’s Caremark business experienced a halt in prescription processing, leaving some without their medications.

CVS Health Corp’s (NYSE:CVS) unit, Caremark, noted an “unexpected system slowdown” in a letter dispatched to pharmacists on Monday.

This issue affected all types of businesses managed by CVS Caremark, which funds prescriptions at thousands of drugstores, including those beyond the company’s outlets.

On Tuesday, a CVS Health spokesperson mentioned that a system issue impacted Caremark’s prescription billing and e-prescriptions. While the system is now operational, there might be temporary delays due to a backlog of prescriptions, Wall Street Journal reported. The cause of the issue was not disclosed.

According to the Drug Channels Institute, CVS Caremark, which processed 2.3 billion claims in the previous year, represents about a third of the market.

Carter High, co-owner of Best Value Pharmacies, reported prescription processing issues via CVS Caremark’s system starting Monday morning at his stores in the Fort Worth area.

High faced difficulties checking customers’ coverage, and he couldn’t determine whether the prescription would be paid for or how much the customer should be charged out-of-pocket.

Consequently, some customers were asked to return the following day unless they were willing to pay the full cost of the prescription up front.

The outage persisted throughout Monday, but prescriptions were being processed again by Tuesday morning, albeit with some delays.

Price Action: CVS shares are up 0.15% at $71.38 premarket on the last check Wednesday.

Photo via Wikimedia Commons

Total
0
Shares
Related Posts
Read More

Sana Biotechnology Announces Publication Of Preclinical Diabetes Data In Cell Stem Cell Demonstrating Insulin Independence Following Transplantation Of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression In A Diabetic NHP

Transplant of HIP-modified pancreatic islet cells provided lasting glucose control in a fully immunocompetent non-human primate (NHP), enabling the achievement of exogenous insulin independence without immunosuppression

SANA